Keywords
PD-1
Mestizos venezolanos Type 1 autoimmune hepatitis
PD-1
Venezuelan mestizos
How to Cite
Abstract
Introduction: Autoimmune hepatitis (AIH) is a progressive liver disease showing genetic susceptibility. The inhibitory PD-1 molecule acts as a surface receptor. One of the SNPs, PD-1.3G/A has been associated with susceptibility to autoimmune diseases. Experimental findings suggest that PD-1 may play an important role in the development of autoimmune liver pathologies. Objective: to establish the PD-1 gene polymorphism (PD-1.3 G/A) and its potential association to type 1 AIH in Venezuelan mestizo patients. Methodology: 70 patients with type 1 AIH and 120 healthy individuals were studied, both groups being third generation Venezuelans. The determination of the polymorphisms was done through PCR, using specific oligonucleotide initiators followed by restriction enzyme digestion (PstI). Results: the most frequent allele in both population groups was the wild G allele (92.9% and 95.4%) with very similar frequencies. The most frequent phenotype was the wild homozygote genotype (G/G), both in patients and controls (87.2% and 90.8%, p=0.42) with higher values observed in the second group. The G/A genotype is more often found among patients (11.4% vs 9.2%, p=0.62). The A/A homozygote genotype was only present in one patient and in none of the controls (1.4% vs 0%, p=0.19). None of these differences was significant. Conclusion: no difference was found in the genotype distribution of the PD-1 gene (PD-1.3G/A) observed in patients and healthy individuals, which suggests that in our population the susceptibility for Type 1 AIH is not affected by this gene’s polymorphism.
References
Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-9. https://doi.org/10.1034/j.1600-0528.2002.017401.x
Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Archi Dis Child 1992;67:1447-53. https://doi.org/10.1136/adc.67.12.1447
Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22(4): 353-63. https://doi.org/10.1055/s-2002-35705
Fortes MP, Machado IV, Gil GC, Fernández-Mestre M, Dagher L, León R, Bianco N.E, et al. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. Liver International 2007;27: 1409-16. https://doi.org/10.1111/j.1478-3231.2007.01581.x
Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type I autoimmune hepatitis. Clin Liver Dis 2002;6:707-25. https://doi.org/10.1016/S1089-3261(02)00023-5
Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, Lorenz M et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004;20(3):337-47. https://doi.org/10.1016/S1074-7613(04)00051-2
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO 1992;11:3887-95. https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
Freeman GJ,Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34. https://doi.org/10.1084/jem.192.7.1027
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53. https://doi.org/10.1158/1078-0432.CCR-04-1469
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proct Natl AcadSci USA 2004;101:17174-79. https://doi.org/10.1073/pnas.0406351101
Oikawa T, Takahashi H, Ishikawa T, Hokari A, Otsuki N et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. PatholInt 2007;57(8):485-92. https://doi.org/10.1111/j.1440-1827.2007.02129.x
Mataki N, Kikuchi K, Kawai T, Higashiyama M, Okada Y et al. Am J Gastroenterol 2007;102(2):302-12. https://doi.org/10.1111/j.1572-0241.2006.00948.x
Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 1997;197:177-87. https://doi.org/10.1016/S0378-1119(97)00260-6
Prokunina L, Castillejo-Lopez C, Oberg F, GunnarssonI, BergL, MagnussonV et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666-9. https://doi.org/10.1038/ng1020
Velázquez-Cruz R, Orozco L, Espinosa-Rosales F, Carreño-Manjarrez R, Solís-Vallejo E, López-Lara ND et al. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur J HumGenet 2007;15(3):336-41. https://doi.org/10.1038/sj.ejhg.5201767
Ferreiros-Vidal I,Gomez-Reino J ,BarrosF,CarracedoA,Carreira P, Gonzáles-Escribano F. Association of PDCD1 with susceptibility to systemic lupus erythematosus. Arthritis Rheumat 2004;50(8):2590-7. https://doi.org/10.1002/art.20436
Prokunina L, Padyukov L, Bennet A, de Faire U, Wiman B, Prince J et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor the shared epitope. Arthritis Rheum 2004;50(6):1770-3. https://doi.org/10.1002/art.20280
Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type I diabetes. Tissue Antigens 2003;62(6):492-7. https://doi.org/10.1046/j.1399-0039.2003.00136.x
Lee SH, Lee YA, Woo DH, Song R, Park EK, Ryu MH et al. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 2006;8(6):R163. https://doi.org/10.1186/ar2071
Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:2051-7. https://doi.org/10.1111/j.1572-0241.2002.05921.x
Shangera DK, Manzi S, Bontempo F, Nestlerode C, Kamboh MI. Role of an intronic polymorphism in the PDCD1 gene with the risk of sporadic systemic lupus erythematosus and the occurrence of antiphospholipid antibodies.Hum Genet 2004; 115(5): 393-98. https://doi.org/10.1007/s00439-004-1172-0
Daniel, W. Bioestadística. Base para el Análisis de las Ciencias de la Salud. Editorial Limusa-Wiley. 4ta edición. México, 2002:228-55.
Ferreiros-Vidal I, D'Alfonso S, Papasteriades C, Skopouli F, Marchini M et al. Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe. Genes Immun 2007;8:138-46. https://doi.org/10.1038/sj.gene.6364370
Kong EK, Prokunina-Olsson L, Wong WH, Lau CH, ChanTK et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005;52:1058-62. https://doi.org/10.1002/art.20966
Mori M, Yamada R, Kobayashi K, Kawaida R, Yamamoto K. Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J Hum Genet 2005; 50(5):264-66. https://doi.org/10.1007/s10038-005-0246-8
Fortes MP, Gil G, Paredes ME, Gámez LE, Palacios M et al. Allele and haplotype frequencies at human leucocyte antigen class I and II genes in Venezuela's population. Ann Biol Clin 2012;70(2):175-81." https://doi.org/10.1684/abc.2012.0663